[1]王静翠,谢佳利,何 昆,等.国家药品集中采购政策对口服降糖药的长期影响与替代效应研究 ——基于四川省实证数据[J].卫生经济研究,2026,43(01):19-25.
　WANG Jingcui,XIE Jiali,HE Kun,et al.Research on the Long-Term Impact and Substitution Effect of the National Volume-Based Procurement Policy on Oral Antidiabetic Drugs——An Empirical Analysis Based on Procurement Data from Sichuan Province[J].Journal Press of Health Economics Research,2026,43(01):19-25.
点击复制

国家药品集中采购政策对口服降糖药的长期影响与替代效应研究
——基于四川省实证数据

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年01期
页码:
19-25
栏目:
药械管理
出版日期:
2026-01-06

文章信息/Info

Title:
Research on the Long-Term Impact and Substitution Effect of the National Volume-Based Procurement Policy on Oral Antidiabetic Drugs
——An Empirical Analysis Based on Procurement Data from Sichuan Province
作者:
王静翠1; 2; 谢佳利1; 何 昆3; 许凌巧3; 武志昂1; 4; 唐晓蓉3; 胡 明1
1.四川大学华西药学院，四川 成都 610041
2.四川大学华西乐城医院，海南 琼海 361003
3.四川省药械招标采购服务中心，四川 成都 610016
4.沈阳药科大学亦弘商学院，辽宁 沈阳 110016
Author(s):
WANG Jingcui;  XIE Jiali;  HE Kun;  XU Lingqiao;  WU Zhi'ang;  TANG Xiaorong;  HU Ming
West China School of Pharmacy, Sichuan University, Chengdu Sichuan 610041, China
关键词:
药品集中采购; 口服降糖药; 替代效应; 长期效应; 间断时间序列分析
Keywords:
volume-based procurement;  oral antidiabetic drugs;  substitution effect;  long-term effect;  interrupted time series analysis
分类号:
R19
文献标志码:
A
摘要:
目的：分析国家组织药品集中采购政策对口服降糖药的长期影响和替代效应。方法：基于四川省公立医疗机构的口服降糖药采购数据，分析集中采购政策实施前后药品的量价关系。结果：集中采购政策实施后，口服降糖药均价下降2.24元（P<0.05），采购量持续上升，量价关系呈显著负相关（P<0.05）；仿制药月均采购量占比从78.9%提升至86.5%，价格降幅显著高于原研药；中选品种采购量增幅超过50倍，价格下降，而非中选品种价格变化不明显；集采品种采购量显著增加，采购单价下降，但临床可替代品种的采购量持续上升，价格趋势无显著变化。结论：集中采购政策有效降低了药品价格、提升了药品可及性，并促进了仿制药替代，但对非中选及临床可替代品种的价格影响有限；未来政策应强化临床价值导向，通过精细化管理扩大政策覆盖范围，推动药品价格合理回归。
Abstract:
Objective To analyze the long-term impact and substitution effect of the National Volume-Based Procurement(NVBP) policy on oral antidiabetic drugs(OADs). Methods Based on procurement data of OADs from public medical institutions in Sichuan Province, the volume-price relationship of drugs before and after the implementation of the NVBP policy was analyzed. Results After the policy implementation, the average price of OADs decreased by 2.24 yuan(P<0.05), while procurement volume continued to increase, showing a significant negative correlation between volume and price(P<0.05). The average monthly procurement share of generic drugs increased from 78.9% to 86.5%, with significantly greater price reductions compared to originator drugs. The procurement volume of selected (winning bid) drugs increased by more than 50-fold with price decreases, whereas the prices of non-selected drugs showed no significant change. Although the procurement volume of NVBP drugs increased significantly and their unit prices decreased, the procurement volume of clinically substitutable alternatives continued to rise without significant price changes. Conclusion The NVBP policy effectively reduced drug prices, improved drug accessibility, and promoted generic substitution, but its impact on the prices of non-selected and substitutable drugs was limited. Future policies should strengthen clinical value orientation, expand policy coverage through refined management, and promote the rational return of drug prices.

参考文献/References:

[1] Deng W, Zhao L, Chen C, et al. National burden and risk factors of diabetes mellitus in China from 1990 to 2021: results from the Global Burden of Disease study 2021[J]. J Diabetes, 2024,16(10):e70012.
[2] 中国2型糖尿病防治指南（2020年版）（上）[J].中国实用内科杂志，2021，41（08）：668-695.
[3] Wang N, Yang Y, Xu L, et al. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis[J]. BMC Public Health, 2021, 21(01): 1883.
[4] Wang J, Zhang S, Wang C, et al. The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China[J]. BMC Health Serv Res, 2024, 24(01): 771.
[5] Wang X, He X, Zhang P, et al. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis[J]. Int J Equity Health, 2023, 22(01): 200.
[6] Long H, Yang Y, Geng X, et al. Changing characteristics of pharmaceutical prices in China under centralized procurement policy: a multi-intervention interrupted time series[J]. Front Pharmacol, 2022, 13: 944540.
[7] Yang C, Ye D, Yan K, et al. The impacts of the national centralized drug procurement policy on the use of policy-related antibiotic agents: the case of Shaanxi province, China[J]. Expert Rev Anti Infect Ther, 2023, 21(06): 675-684.
[8] 杨莹，崔丹，毛宗福.我国药品集中带量采购制度理论与实践浅析[J].中国医疗保险，2024（09）：57-63.
[9] Lu J, Long H, Shen Y, et al. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China[J]. Front Pharmacol, 2022, 13: 923209.
[10] Wagner A K, Soumerai S B, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research[J]. J Clin Pharm Ther, 2002, 27(04): 299-309.
[11] World Health Organization. Defined Daily Dose(DDD)[EB/OL].[2025-02-25]. https://www.who.int/tools/atc-ddd-toolkit/about-ddd.
[12] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2024[EB/OL]. [2024-12-31]. https://atcddd.fhi.no/atc_ ddd_index.
[13] Ha J, Kose M A, Ohnsorge F, et al. What Explains Global Inflation. IMF Econ Rev(2024). https://doi.org/10.1057/s41308-024 -00255-w.
[14]国家统计局.2025年1—9月份全国规模以上工业企业利润增长3.2%[EB/OL].[2025-02-25].https://www.stats.gov.cn.
[15] Landsman P B, Yu W, Liu X, et al. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization[J]. The American Journal of Managed Care, 2005, 11(10): 621-628.
[16] Yang Y, Hu R, Geng X , et al. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China[J]. Int J Health Plann Manage, 2022, 37(03): 1650-1662.
[17] Zhang Jing, Wenjia Wang. The Impact of Centralized Drug Procurement on Drug Prices and Utilization in China[R]. Asia Health Policy Program, 2022.
[18] Velásquez J V, Portilla K G, Vélez E A, et al. Elasticidad de la demanda por medicamentos en el mercado farmacéutico privado en Colombia[J]. Ecos de Economía, 2013,17: 147-172.
[19] Srivastava, Divya. An analysis of the determinants of access to medicines and health care in developing country settings[D]. Ann Arbor: ProQuest Dissertations & Theses, 2011.
[20] Ke Z, Zhang Y, Duan D. Effect of centralized volume-based procurement of drugs on business performance of listed pharmaceutical enterprises[J]. Heliyon, 2024, 10(12): e33198.
[21] 薛天祺，路云，常峰.国家药品集中带量采购中选结果及采购规则优化方向分析[J].卫生经济研究，2022，39（05）：12-16.

相似文献/References:

[1]袁 姣,刘杨正,左克源,等.基于药品集中采购的供应链融资模式研究[J].卫生经济研究,2017,(01):50.
[2]周 苑,汤质如,刘守明,等.药品集中采购模式研究及问题探讨[J].卫生经济研究,2018,(03):26.
[3]吴 天.药品集中采购价格与药品费用控制研究[J].卫生经济研究,2018,(12):32.
　WU Tian.Research on Centralized Purchasing Price and Drug Cost Control of Medicines[J].Journal Press of Health Economics Research,2018,(01):32.
[4]薛天祺,路 云,常 峰.国家药品集中带量采购中选结果及采购规则优化方向分析[J].卫生经济研究,2022,39(5):12.
　XUE Tian-qi,LU Yun,CHANG Feng.Analysis of Selected Results and Rule Optimization Direction of National Pharmaceutical Centralized Volume-Based Procurement[J].Journal Press of Health Economics Research,2022,39(01):12.
[5]丁瑞琳,颜建周,李馨雨,等.定点零售药店纳入门诊统筹管理政策的实施难点分析[J].卫生经济研究,2025,42(09):14.
　DING Ruilin,YAN Jianzhou,LI Xinyu,et al.Analysis of the Implementation Difficulties of the Policies for Incorporating Designated Retail Pharmacies into Outpatient Pooling Fund Management[J].Journal Press of Health Economics Research,2025,42(01):14.

更新日期/Last Update: 2026-01-06